<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib4">
 <element-citation publication-type="book" id="sref4">
  <person-group person-group-type="author">
   <name>
    <surname>Association</surname>
    <given-names>F.-D.</given-names>
   </name>
  </person-group>
  <chapter-title>FDA Approves Gamifant® (Emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH). Business Wire</chapter-title>
  <year>2018</year>
  <publisher-name>Business Wire, Inc</publisher-name>
  <comment>Retrieved 21 November 2018</comment>
  <ext-link ext-link-type="uri" xlink:href="https://www.businesswire.com/news/home/20181120005454/en/FDA-Approves-Gamifant%ae-emapalumab-lzsg-Treatment-Primary-Hemophagocytic" id="intref0015" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.businesswire.com/news/home/20181120005454/en/FDA-Approves-Gamifant®-emapalumab-lzsg-Treatment-Primary-Hemophagocytic</ext-link>
 </element-citation>
</ref>
